Transcriptome analysis reveals differentially expressed genes between human primary bone marrow mesenchymal stem cells and human primary dermal fibroblasts

Ekim Zihni TAŞKIRAN*, Beren KARAOSMANOĞLU
Department of Medical Genetics, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Abstract: Stromal cells have been widely used in biomedical research and disease modeling studies in vitro. The most commonly used types of stromal cells are mesenchymal stem cells and fibroblasts. Their cellular phenotypes and differentiation capabilities are quite similar and there are no specific distinction criteria. In order to identify transcriptomic differences between these 2 cell types, we performed next-generation RNA sequencing. Using the global gene expression profile and pathway analysis, we showed that human primary bone marrow mesenchymal stem cells and human primary dermal fibroblasts have different molecular signatures. We also identified critical transcription factors that are differentially expressed between these cells. We then proposed that homeobox genes and some other sequence-specific transcription factors are not only responsible for transcriptional differences, but also discriminate bone marrow mesenchymal stem cells and dermal fibroblasts at the transcriptional level.

Key words: Human bone marrow mesenchymal stem/stromal cells, human dermal fibroblasts, transcriptomics, gene expression

1. Introduction
Stromal cells have been widely used in biomedical research and disease modeling studies in vitro. One of the most important types of stromal cells is the mesenchymal stem/stromal cell (MSC). MSCs are multipotential stem cells that originate from mesenchyme and can be isolated from many tissues, but mainly from bone marrow and adipose tissues (Charbord, 2010; Hass, 2011). Bone marrow mesenchymal stem/stromal cells (BM-MSCs) are positive for specific surface markers CD90, CD73, and CD105 and negative for specific surface markers CD45, CD34, CD14, and CD19 according to the International Society for Cellular Therapy (ISCT) (Bae, 2009; Charbord, 2010; Pontikoglou, 2011). They are spindle-shaped adherent cells and have the capacity to differentiate into cell types of this lineage such as adipocyte, osteocyte, chondrocyte, myocyte, tendonocyte, and ligamentocyte (Pontikoglou, 2011). They are one of the most important members of bone marrow and responsible for stromal support. In addition, they are capable of migrating into damaged tissue and play a major role in repair or regeneration of that tissue. They have high regeneration potential and immune modulatory properties (Charbord, 2010; Eggenhofer, 2014). These features make MSCs very advantageous for regenerative medicine and therapeutic approaches.

Another type of stromal cell is the dermal fibroblast (DF), which may be obtained easily from skin biopsy or different surgical materials. DFs are mainly responsible for extracellular matrix (ECM) synthesis; they are found in the dermal layer of the skin. Fibroblasts that are derived from this layer are responsible for forming connective tissue and play a major role in wound healing or repair at injury sites (Driskell, 2015). Thus, they provide healing and recovery in almost all tissues. However, activation and proliferation of fibroblasts sometimes lead to fibrosis or scar formation (Driskell, 2013). BM-MSCs and DFs may not be distinguished by their cellular morphology or surface markers (Bae, 2009; Denu, 2016; Ichim, 2018; Kundrotas, 2012; Soundararajan, 2018). Due to their common properties, there should be a detailed study in order to reveal their differential characteristics. Transcriptomic studies are highly important for evaluating cell-specific characteristics (Kasoju, 2017). The aim of this study is to reveal the transcriptomic profiles of human BM-MSCs and DFs in order to identify discriminating markers.

2. Materials and methods
2.1. Cell culture and RNA isolation
Human primary bone marrow mesenchymal stem/stromal cells (BM-MSCs) (Cat. No: PCS-500-012**) and Human primary dermal fibroblasts (DFs) (Cat. No: PCS-201-012**)
were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). BM-MSCs were obtained from a 24-year-old male Caucasian donor’s bone marrow aspirate (Lot: 63208778) and DFs were obtained from a 28-year-old male African–American donor’s abdominal skin (Lot: 63792061). Cells were incubated at 37 °C, 5% CO₂ conditions; passage 3 cells were used, and all samples were prepared in triplicate. Culture medium (DMEM-LG, 10% FBS, 1% Pen/Strep, 1% L-glutamine) was changed twice a week. After reaching nearly 70%–80% confluency, cells were washed with PBS and treated with TRI Reagent® for RNA isolation (Sigma, St. Louis, MO, USA). RNA was isolated according to the manufacturer’s instructions. RNA quality was measured with a Nanodrop® (Thermo Fisher Scientific, Waltham, MA, USA) spectrophotometer and quantity was measured with a Qubit® (Thermo Fisher Scientific) fluorometer.

2.2. Quantitative transcriptome analysis
For library preparation, a barcoded cDNA library was first generated with a SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific) from 10 ng of total RNA sample. An Ampliciseq Human Gene Expression Chef Ready Kit (Thermo Fisher Scientific) was used for targeted amplification of nearly 20,000 distinct mRNA targets. Libraries were then generated by an Ion Chef instrument (Thermo Fisher Scientific), and pooled libraries were clonally amplified using emulsion PCR on an Ion Torrent OneTouch2 (OT2) instrument (Thermo Fisher Scientific). Enrichment was done using an Ion OneTouch ES instrument (Thermo Fisher Scientific). The templated libraries were then sequenced on an Ion Proton semiconductor sequencing system, using an Ion PI Hi-Q Sequencing Kit and Ion PI chip v3 (Thermo Fisher Scientific). All next-generation sequencing experiments were performed in duplicate.

2.3. Data analysis
The sequencing data were processed by the Torrent Suite analysis pipeline. Raw reads were mapped to the human genome assembly hg19 AmpliSeq Transcriptome version by TMAP (Torrent mapping alignment program). The data were normalized and differentially expressed genes (DEG) were determined with DESeq2. STRING (version 10.5) was used to identify associations between the significant genes (http://string-db.org/).

3. Results
We found that 419 and 773 genes were upregulated in Human Primary BM-MSCs and in Human Primary DFs, respectively. Volcano plot indicated that these gene expression changes were statistically significant (Figure 1). We then continued further analysis with these differentially expressed genes (DEGs).

![Figure 1. Volcano plot of differentially expressed genes between BM-MSCs (red) and DFs (blue) (log₂ fold change versus –log₁₀ false discovery rates).](image)

We performed STRING analysis for protein interactions and connections with upregulated genes in BM-MSCs. We found higher interaction between immune-system–related genes (IL6, VEGFA, TNF, TGFB2, CCL2, IL12B, HLA-DPA1, CD4, IL16, SAA1, FPR1, FPR2, CFI, and CFH) in BM-MSCs (Figure 2). Pathway analysis showed that most of the DEGs in BM-MSCs were significantly enriched regarding receptor binding, sequence-specific DNA binding, protein binding, growth factor activity, transcriptional activator activity, and extracellular matrix structural constituent (Table 1).

STRING analysis showed that DEGs in DFs were also closely related (Figure 3). According to pathway analysis of DEGs in DFs were significantly enriched regarding transmembrane signaling receptor activity, signaling receptor activity, signal transducer activity, receptor activity, molecular transducer activity, and G-protein coupled receptor activity and calcium ion binding (Table 2).

Because sequence-specific DNA binding proteins showed different expression patterns between BM-MSCs and DFs, we first examined all of the probable functional homeobox genes in detail (Holland, 2007). In this examination, homeobox genes showed cell-specific expression pattern. ALX1, DLX1, DLX5, DLX6, IRX3, PITX2, SHOX, SIX1, SIX2, and ZFHX4 were highly expressed in BM-MSCs, while EMX2, IDX1, MEIS1, MEIS2, MEIS3, MSX1, PAX3, PBX1, PBX3, and SHOX2 were highly expressed in DFs (Figures 4A and 4B). In addition to homeobox genes, we found that some of the other transcription factors that are important for several biological functions were highly expressed in BM-MSCs (Figure 5).
4. Discussion

To date, there have been many studies on the similarities and differences between MSCs and DFs (Bae, 2009; Ichim, 2018; Kundrotas, 2012; Ulrich, 2012; Soundararajan, 2018). However, there is no agreement about the exact discrimination of these cells yet. Previous studies about transcriptomic profiling of stromal cells were accomplished with microarray-based techniques (Bae, 2009). Herein, we performed up-to-date next-generation sequencing technology to quantify transcriptomic differences. By using next generation RNA-sequencing we obtained more detailed data including even low-level transcripts (Li, 2015). We first identified differentially expressed genes between Human Primary BM-MSCs and Human Primary DFs, and then focused on the expression levels of some transcription factors which could be responsible for gene expression differences between these 2 cell types. Comparative analysis showed that BM-MSCs and DFs are distinguishable according to their global gene expression profile.
We observed that homeobox genes were differentially expressed between BM-MSCs and DFs. The homeobox genes are a large group of genes which play important roles in embryonic development (Seifert, 2015). They encode transcription factors regulating cellular processes such as proliferation and migration. According to our analysis, DLX1, DLX5, and DLX6 were predominantly expressed in BM-MSCs. It has been shown in recent studies that some members of the DLX (distal-less homeobox) family are responsible for osteogenic differentiation and craniofacial development (Charite, 2001; Li, 2008; Heo, 2017). The aristaless-like homeobox family member ALX1, which is necessary for the development of the head and face, is also more highly expressed in BM-MSCs than in DFs (Zhao, 1996). Another highly expressed homeobox gene in BM-MSCs is SHOX, which regulates the expression of early osteogenic genes during differentiation (Yokokura, 2017). When all of these are taken into account, one could think that for studying developmental gene expression networks and osteogenic differentiation stages, BM-MSCs are more appropriate than DFs.

The predominantly expressed homeobox genes in DFs mainly belong to the TALE (three amino acid loop extension) homeobox family (IRX1, MEIS1, MEIS2, MEIS3, and PBX1). Unlike other genes within homeobox genes, TALE group members are widely expressed rather than cell/tissue-specific (Dunwell, 2016). The stromal cell-specific functions of these have not yet been reported. However, due to the presence of studies that link fibrosis with some homeobox genes, their role in this condition should be investigated in detail (Wandzioch, 2004; Zhou, 2014; Gong, 2017).

There are also some critical targets, predominantly expressed in BM-MSCs, which could be the basis of gene expression differences between these 2 cell types. According to recent publications, most of the differentially expressed transcription factors have critical roles in stem cell biology. For example, it has been shown that SOX family members are responsible for cell fate decisions, and it has also been shown that SOX11, GATA6, and PRDM16 have critical roles in MSC self-renewal (Kubo, 2009; Sarkar, 2013). Additionally, FOXC1, highly expressed in BM-MSCs, is identified as a key player in the bone marrow niche (Omatsu, 2014). When we tried to identify the master regulator of immune-system–related genes in our data, we showed that EGR2 (early growth response

| Pathway ID   | Pathway description                                                                 | Observed gene count | False discovery rate |
|--------------|-------------------------------------------------------------------------------------|---------------------|---------------------|
| GO:0005102   | Receptor binding                                                                    | 48                  | 2.5e-05             |
| GO:0043565   | Sequence-specific DNA binding                                                        | 40                  | 3.85e-05            |
| GO:0005515   | Protein binding                                                                     | 117                 | 0.00511             |
| GO:0008083   | Growth factor activity                                                              | 9                   | 0.00856             |
| GO:0001228   | Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding | 18                  | 0.0121             |
| GO:0000976   | Transcription regulatory region sequence-specific DNA binding                       | 24                  | 0.0137             |
| GO:0005201   | Extracellular matrix structural constituent                                         | 8                   | 0.0137             |
| GO:1901681   | Sulfur compound binding                                                             | 14                  | 0.0137             |
| GO:000982    | Transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding | 17                  | 0.0252             |
| GO:001077    | Transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding | 14                  | 0.0252             |
| GO:0005539   | Glycosaminoglycan binding                                                            | 13                  | 0.0252             |
| GO:0008201   | Heparin binding                                                                     | 11                  | 0.0252             |
| GO:0044212   | Transcription regulatory region DNA binding                                         | 26                  | 0.0252             |
| GO:0005126   | Cytokine receptor binding                                                            | 13                  | 0.0335             |
| GO:0015077   | Monovalent inorganic cation transmembrane transporter activity                      | 17                  | 0.0431             |
| GO:0005261   | Cation channel activity                                                             | 15                  | 0.0436             |
| GO:007851    | Growth factor receptor binding                                                       | 8                   | 0.0436             |
**Table 2.** DEGs in DFs annotated using gene ontology molecular function.

| Pathway ID   | Pathway description                     | Observed gene count | False discovery rate |
|--------------|----------------------------------------|---------------------|----------------------|
| GO:0004888   | Transmembrane signaling receptor activity | 81                  | 2.9e-09              |
| GO:0038023   | Signaling receptor activity             | 85                  | 2.9e-09              |
| GO:0004871   | Signal transducer activity              | 98                  | 3.58e-09             |
| GO:0004872   | Receptor activity                       | 92                  | 3.58e-09             |
| GO:0060089   | Molecular transducer activity           | 105                 | 4.03e-09             |
| GO:0004930   | G-protein coupled receptor activity     | 57                  | 1.35e-06             |
| GO:0005509   | Calcium ion binding                     | 44                  | 0.00503              |

**Figure 3.** STRING output of network analysis of the DEGs in DFs (confidence score = 0.900).
2) transcription factor was highly expressed in BM-MSCs but not in DFs. It is known that EGR2 is responsible for mediating the expression of immune-system–related genes in MSCs (Barbeau, 2014). We proposed that expression levels of all these transcription factors could be used as discriminating markers between BM-MSCs and DFs.

This is an example of RNA-sequencing–based transcriptomics regarding comparison of different stromal cells. Future studies should focus on stage- and/or disease-specific transcriptomic signatures between different types of stromal cells. By doing this, biological functions and therapeutic potentials of stromal cells could be identified in detail.
References

Bae S, Ahn JH, Park CW, Son HK, Kim KS, Lim NK, Jeon CJ, Kim H (2009). Gene and microRNA expression signatures of human mesenchymal stromal cells in comparison to fibroblasts. Cell Tissue Res 335: 565-573.

Barbeau DJ, La KT, Kim DS, Kerpeldijeva SS, Shurin GV, Tamama K (2014). Early growth response-2 signaling mediates immunomodulatory effects of human multipotential stromal cells. Stem Cells Dev 23: 155-166.

Charbord P (2010). Bone marrow mesenchymal stem cells: historical overview and concepts. Human Gene Therapy 21: 1045-1056.

Charité J, McFadden DG, Merlo G, Levi G, Clouthier DE, Yanagisawa M, Richardson JA, Olson EN (2001). Role of DLx6 in regulation of an endothelin-1-dependent, dHAND branchial arch enhancer. Genes Dev 15: 3039-3049.

Denu RA, Nemcek S, Bloom DD, Goodrich AD, Kim J, Mosher DF, Hematti P (2016). Fibroblasts and mesenchymal stromal/stem cells are phenotypically indistinguishable. Acta Haematol 136: 85-97.

Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Heraly Y, Pavlović G, Ferguson-Smith AC et al. (2013). Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 504: 277-281.

Driskell RR, Watt FM (2015). Understanding fibroblast heterogeneity in the skin. Trends Cell Biol 25: 92-99.

Dunwell TL, Holland PW (2016). Diversity of human and mouse homeobox gene expression in development and adult tissues. BMC Dev Biol 16: 40.

Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ (2014). The life and fate of mesenchymal stem cells. Front Immunol 5: 148.

Gong J, Han J, He J, Liu J, Han P, Wang Y, Li M, Li D, Ding X, Du Z et al. (2017). Paired related homeobox protein 1 regulates PDGF-induced chemotaxis of hepatic stellate cells in liver fibrosis. Lab Invest 97: 1020-1032.

Hass R, Kasper C, Böhmi S, Jacobs R (2011). Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 9: 12.

Heo JS, Lee SG, Kim HO (2017). Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells. Int J Mol Med 40: 1486-1494.

Holland PW, Booth HA, Bruford EA (2007). Classification and nomenclature of all human homeobox genes. BMC Biol 5: 47.

Ichim TE, O’Heeron P, Kesari S (2018). Fibroblasts as a practical alternative to mesenchymal stem cells. J Transl Med 16: 212.

Kasoji N, Wang H, Zhang B, George J, Gao S, Triffitt JT, Cui Z, Ye H (2017). Transcriptomics of human multipotent mesenchymal stromal cell: Retrospective analysis and future prospects. Biotechnol Adv 35: 407-418.

Kubo H, Shimizu M, Taya Y, Kawamoto T, Michida M, Kaneko E, Igarashi A, Nishimura M, Segoshi K, Shimazu Y et al. (2009). Identification of mesenchymal stem cell (MSC)-transcription factors by microarray and knockdown analyses, and signature molecule-marked MSC in bone marrow by immunohistochemistry: Genes Cells 14: 407-424.

Kundrotas G (2012). Surface markers distinguishing mesenchymal stem cells from fibroblasts. Acta Medica Lituanica 19: 75-79.

Li H, Marijanovic I, Kronenberg MS, Erceg I, Stover ML, Velonis D, Mina M, Heinrich JG, Harris SE, Upholt WB et al. (2008). Expression and function of Dlx genes in the osteoblast lineage. Dev Biol 316: 458-470.

Li W, Turner A, Aggarwal P, Matter A, Stovick E, Arnett DK, Broeckel U (2015). Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genomics 16: 1069.

Omatsu Y, Seike M, Sugiyama T, Kume T, Nagasawa T (2014). Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature 508: 536-540.

Pontikoglou C, Deschaseaux F, Sensebé L, Papadaki HA (2011). Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev and Rep 7: 569-589.

Sarkar A, Hockedlinger K (2013). The SOX family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell 12: 15-30.

Seifert A, Werheid DE, Knapp SM, Tobiasch E (2015). Role of Hox genes in stem cell differentiation. World J Stem Cells 7: 583-595.

Soundararajan M, Kannan S (2018). Fibroblasts and mesenchymal stem cells: two sides of the same coin? J Cell Physiol 233: 9099-9109.

Ulrich C, Hart ML, Rolauffs B, Abele H, Götze M et al. (2012). Mesenchymal stromal cells and fibroblasts. J Tissue Sci Eng 3: 109.

Wandzioch E, Kolterud A, Jacobsson M, Friedman SL, Carlsson L, USA 101: 16549-16554.

Yokokura T, Kamei H, Shibano T, Yamanaka D, Sawada-Yamaguchi R, Hakuno F, Takahashi S, Shimizu T, (2017). The short-stature homeotic mutant for the Cart1 homeobox gene. Nat Genet 13: 275-283.

Zhou TB, Ou C, Qin YH, Lei FY, Huang W, Drummep GN (2014). LIM homeobox transcription factor 1B expression affects renal interstitial fibrosis and apoptosis in unilateral ureteral obstructed rats. Am J Physiol Renal Physiol 306: 1477-1488.